Cysteine decrease following acute Levodopa intake in patients with Parkinson's disease

Neuroscience Letters

Volumn 521, Issue 1, 2012, Pages 37-39

  Müller, Thomas ^a,b   Muhlack, Siegfried ^b  

^a St Joseph Hospital Berlin Weissensee   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

Cysteine; Free radicals; Glutathione; Parkinson's disease

Indexed keywords

BENSERAZIDE; CARBIDOPA; CYSTEINE; ENTACAPONE; FREE RADICAL; GLUTATHIONE; LEVODOPA; RASAGILINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYNTHESIS; UPREGULATION;

ADMINISTRATION, ORAL; ANTIPARKINSON AGENTS; CARBIDOPA; CYSTEINE; DOPA DECARBOXYLASE; DRUG COMBINATIONS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84862599656     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.05.054     Document Type: Article

References (6)

1. Allain P., Le B.A., Cordillet E., Le Q.L., Bagheri H., Montastruc J.L. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology 1995, 16:527-529.
2. Holmgren A., Johansson C., Berndt C., Lonn M.E., Hudemann C., Lillig C.H. Thiol redox control via thioredoxin and glutaredoxin systems. Biochemical Society Transactions 2005, 33:1375-1377.
3. Kuhn W., Roebroek R., Blom H., van O.D., Przuntek H., Kretschmer A., Büttner T., Woitalla D., Müller T. Elevated plasma levels of homocysteine in Parkinson's disease. European Neurology 1998, 40:225-227.
4. Müller T., Kuhn W. Cysteine elevation in levodopa-treated patients with Parkinson's disease. Movement Disorders 2009, 24:929-932.
5. Riederer P., Gerlach M., Müller T., Reichmann H. Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. Parkinsonism & Related Disorders 2007, 13:466-479.
6. Riederer P., Lachenmayer L., Laux G. Clinical applications of MAO-inhibitors. Current Medicinal Chemistry 2004, 11:2033-2043.